MyMD Pharmaceuticals has secured a 13th U.S. patent protecting its experimental therapy MYMD-1, which is being investigated as a…
Articles by Marisa Wexler, MS
Treatment with two approved antifibrotics did not lessen a risk of death in recently hospitalized idiopathic pulmonary fibrosis (IPF) patients,…
For more than 40% of people with pulmonary fibrosis (PF), obtaining an accurate diagnosis takes a year or longer,…
Measuring the levels of certain molecules in the blood could be useful for distinguishing idiopathic pulmonary fibrosis (IPF) from other…
Switching antifibrotic treatment is generally well-tolerated among people with idiopathic pulmonary fibrosis (IPF), and those who did generally lived…
The Washington Research Foundation (WRF) has awarded a $250,000 grant to support the development of…
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for…
Vicore Pharma and Alex Therapeutics are collaborating to develop a new phone app that could help improve the…
Treatment with Ofev (nintedanib) is safe and can preserve lung function in people with idiopathic pulmonary fibrosis (IPF)…
Axatilimab, an investigational therapy being developed by Syndax Pharmaceuticals, has been granted orphan drug designation by the U.S.